Actions in Peru
RedGE: Why a compulsory license for the antiretroviral atazanavir is important in Peru (en español)
"In Peru, we have obtained one of the best prices in the region for lopinavir + ritonavir, through the availability of generics and competitive bidding. But this situation could be changed by new patent applications. The global campaign enables us to join forces to prevent patent-based monopolies, avoiding catastrophic effects for access to antiretroviral medicines."
-- Javier Llamoza, Health Action International Latin America-Carribean
Peru benefits from generic competition in the market for lopinavir + ritonavir, and has achieved comparatively low prices of $396 per patient per year. While this has enabled the government to provide treatment to over 3,000 patients a year, there is concern that Abbott is seeking a monopoly on lopinavir + ritonavir, as it has registered several patent applications claiming some relation to the medicine.
Health Action International Latin America and PROSA sent a letter to Abbott and the Ministry of Health expressing their concern and asking Abbott to retract its patent applications. Activists also participated in a demonstration before the Ministry of Health.
See the letter to Abbott Laboratories here (in Spanish)
August 14, 2014 - LaRepublica.pe - Sobregasto en medicamentos (en español)
June 19, 2014 - Patente en ARV: Caso atazanavir (courtesy of Javier Llamoza; en español)
April 17, 2014 - Peruvian Civil Society Organizations Demand that Government Issue a Compulsory License for Atazanavir (links to infojustice.org)
Demonstration for the global day of action (11/10/11)
Return to the Kaletra Campaign Homepage